Science1 distinct publisher3 min readUpdated
Low-intensity sound wave treatment for erectile dysfunction is sold session by session in cash-pay clinics. Cochrane reviewed 21 studies and found the results too variable to trust.
The Scientist · Science desk

Compiled by The ScientistSomething wrong?How this is made
A treatment for erectile dysfunction that the U.S. Food and Drug Administration has not approved is being sold, session by session, in American men's health clinics, and leading physician groups decline to support it because evidence of long-term benefit is spotty [1][2]. The gap between commercial scale and evidentiary support is the story here: a course runs six to 12 visits that may cost several hundred dollars each, paid out of pocket [3].
The demand is real. An analysis of 2021 survey data found that 24.2 percent of U.S. men who responded had symptoms consistent with ED, rising to 52.2 percent among those 75 and older [4], roughly 2.2 times the overall rate [5]. Shock wave therapy targets one slice of that: damaged blood flow. James Weinberger, a urological surgeon in Beverly Hills, describes erectile tissue as a sponge that in men with diabetes, high blood pressure or high cholesterol becomes scarred and less able to hold blood under pressure [6]. ED can also stem from medications, anxiety and other nonvascular causes, which this device does not address [7].
On the supply side, Weinberger and colleagues reported in 2022 that at least 152 clinics across eight of the largest U.S. metro areas offered the therapy, and he says that figure "certainly undercounts what exists today" [8][9]. Men's health providers routinely bundle it with testosterone supplementation and medication [10].
The physics is borrowed. High-energy shock waves have shattered kidney stones for decades [11]; the ED version uses low-intensity waves delivered by a wandlike device to several areas of the penis for 15 to 20 minutes, with a snapping sound and, in principle, no pain [12]. Taylor Kohn, a urologist at Baylor College of Medicine, says the energy creates microscopic mechanical stresses at the cellular level, with the theoretical goal of restoring tissue rather than compensating for it the way a pill does [13].
The evidence has not kept pace with the storefronts. The founding result is a 2010 trial in 20 middle-aged men, half of whom, six months out, improved enough for penetrative sex without Viagra-type drugs [14]: ten men [15]. Cochrane's reviewers analyzed 21 studies and concluded the technique might produce a small effect on erectile function in the first few months and could have some longer-term benefit, but variability across the studies shook their confidence [16]. A 2026 report in Sexual Medicine Reviews found the trials small and inconsistent in session count, making them hard to compare, while noting that none reported evidence of harm [17]. Kohn says most trial side effects are skin reactions to the coupling gel [18].
Who holds the wand is the sharper operational point. Among providers at those 152 clinics, only 25 percent were urologists [19]; three in four were not [20], a group that included primary care physicians, plastic surgeons, dermatologists and chiropractors [19]. Weinberger argues that matters because treatment should include conversations about hormones and medications, and stand-alone ED clinics may not offer comprehensive care [21]. Kohn restricts the therapy to men who still respond to oral drugs, saying that for men with no response or no erections at all, "it's kind of a waste of time" [22].
Watch whether the next round of trials standardizes session counts, since that inconsistency is what blunted both reviews [16][17]. Watch for any FDA action [1] and for guideline updates from the American Urological Association and the Sexual Medicine Society of North America, which Science News cites on the evidence question [23]. Until then, with no harm signal in the literature, the exposure a patient carries is mostly financial: at $300 a session, a full course is $1,800 to $3,600 [24].
Follow any of these and your For You feed starts watching them — no settings page required.
Ranked by verification strength, evidence, and original report placement.
Shock wave therapy for erectile dysfunction is not approved by the U.S. Food and Drug Administration.
Leading physician groups do not support shock wave therapy for ED because evidence of long-term benefits is spotty.
James Weinberger, a urological surgeon in Beverly Hills, Calif., says erectile tissue is like a sponge that when healthy fills with blood easily and holds it under pressure, and that in men with vascular risk factors like diabetes, high blood pressure or high cholesterol the tissue can become scarred and less able to hold blood.
ED can occur at any age and be caused by certain medications, anxiety and other nonvascular factors, while shock wave therapy aims to address damaged blood flow.
Science News cites the American Urological Association and the Sexual Medicine Society of North America on the evidence for shock wave therapy for ED; the supplied text of that passage is cut off before their conclusion.
In general, patients come in for six to 12 treatments that may cost several hundred dollars each.
Evidence-backed comparisons of source perspectives and observed adoption signals. Read the methodology
Which Builder, Operator, and Investor concerns the observed source mix emphasized—not a truth score.
Evidence, demonstrated adoption, hype gap, incentives, and confidence are assessed independently, each on its own current evidence. How these are measured.
Weak and heterogeneous clinical evidence
The efficacy base is a 2010 trial of 20 men, a Cochrane review of 21 studies that found at most a small short-term effect with confidence undermined by variability, and a 2026 Sexual Medicine Reviews report describing small studies with inconsistent session counts. Specialty societies conclude the evidence does not justify use outside trials, and there is no FDA approval. Safety evidence is more reassuring than efficacy evidence -- no harm reported, side effects mostly gel-related skin reactions -- which lifts the score off the floor without establishing benefit.
Real commercial footprint, incompletely measured
Adoption is documented on the supply side: at least 152 clinics across eight major metros in a 2022 census the author calls an undercount, a defined six-to-twelve-session cash-pay product, non-urologist providers making up three quarters of those offering it, and routine bundling with testosterone therapy. What is missing is patient volume, national clinic totals, revenue or growth rate, so the score reflects confirmed but unquantified diffusion rather than mass adoption.
Commercial claims run well ahead of evidence
Marketing positions the therapy as a painless path to penile healing and it is sold at scale in structured multi-session courses, while the underlying literature supports at most a small, unreliable short-term effect and the relevant societies restrict it to clinical trials. The gap is amplified by provider mix, since three in four sellers are not urologists, and by patient selection, since the specialist view limits it to men who still respond to oral drugs. The gap is not larger because no source alleges harm and the reporting itself, rather than the promoters, supplies the skeptical framing.
Strong cash-pay revenue incentives on the selling side
The economics reward volume: a non-reimbursed course of six to 12 visits at several hundred dollars each, sold into a population where about a quarter of surveyed men report ED symptoms, cross-sold with testosterone and prescription drugs, and increasingly delivered by clinicians outside urology who face no specialty guideline constraint. Both named experts also have professional positions in the field -- one authored the clinic census and warns against stand-alone competitors, the other researches penile tissue regeneration -- so the cautionary voices carry their own interests. The score is not higher because the supplied sources disclose no ownership, device-vendor or financing relationships to evaluate.
Single-publisher, secondhand evidence trail
All facts come from one outlet, and the pivotal studies -- the Cochrane review, the 2026 Sexual Medicine Reviews report, the 2010 trial, the 2021 prevalence analysis and the 2022 clinic census -- are described without effect sizes or citations available in the supplied material. The account is internally consistent and its two named experts are identifiable and institutionally affiliated, which supports moderate confidence in the direction of the story, but nothing here is independently corroborated and the commercial dimension is unexamined.
science
Focal prostate therapy is drifting outside the guideline that calls it experimental1 distinct publisher
science
Capricor's Duchenne vote is a verdict on design choices made years before the data1 distinct publisher
invest
A policy aide, not a regulator: what Overton's FDA nomination changes for sponsors1 distinct publisher
science
An oral GLP-1 moves the bottleneck from the cold chain to the prescription pad1 distinct publisher
Distinct publishers with included, body-backed reporting in this cluster.
1 article · August 21, 2026